

Intrasense announces its participation in RSNA 2024, the world's leading medical imaging congress

Montpellier, France, November 6, 2024 at 17H45 CEST

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in the RSNA 2024 international imaging congress. Intrasense will be showcasing its new Liflow® solution, as well as the innovations of the new version of Myrian®, on the stand of its partner Guerbet, symbolizing a collaboration serving excellence in medical imaging at a global level.

A strategic presence alongside Guerbet

Intrasense's participation at RSNA 2024 on the booth of its partner Guerbet (n°1711), proves once again the strength of the two companies' commitment to improving the medical imaging sector through artificial intelligence. Intrasense teams will be demonstrating their latest solutions and meeting international industry professionals, with the aim of accelerating the company's growth strategy.

This international leading congress will offer them remarkable exposure from December 1 to 5 at the McCormick Congress Center in Chicago, bringing together over 50,000 participants from 130 countries and some 700 exhibitors. Through a rich program of educational sessions, high-level conferences and specialized workshops, the event aims to share technological and scientific advances in radiology, providing a true crossroads for exchange and innovation.

Innovations in oncology imaging

Liflow®, the new platform developed by Intrasense and awarded the "Prix de l'Innovation" by the Société Française de Radiologie last October, improves diagnostic efficiency and accuracy in oncology imaging. This solution uniquely combines the results of multi-organ artificial intelligence algorithms with patient progress monitoring indicators in a single image.

Liflow® will be the subject of tailor-made demonstrations, highlighting its concrete and unprecedented benefits for clinicians. Enriched with a lung nodule detection AI, and soon with the DUOnco™ Liver AI dedicated to oncology liver analysis, designed in collaboration with Guerbet, Liflow® offers a high-performance solution to the growing needs of practitioners in oncology diagnosis.

In addition, Myrian® advanced radiological visualization platform continues to expand, with advanced intelligent modules dedicated to lung and prostate analysis, reflecting Intrasense's ongoing commitment to supporting healthcare professionals in exam interpretation and pathology follow-up.

Visitors to the congress will be able to see at first-hand how these technologies can improve efficiency and assist diagnosis, thereby helping to improve patient care.

High exposure for Intrasense innovations

In addition to the demonstration areas in the "Innovation" zone on the Guerbet stand, Intrasense's participation in the RSNA congress will be punctuated by several highlights, including conferences dedicated to its innovations, to be held in the "Home of Innovation" area:

- **Monday December 2 at 10:40am: "Liflow® : The power of multi-organ AI in oncology imaging"**
Pr Christophe Aubé, University Professor and Head of the Radiology Department at Angers University Hospital, will discuss the possibilities offered by Liflow® to facilitate oncology analysis.
- **Tuesday December 3 at 10:40am: "Prostate cancer : what contribution can AI make?"**
This symposium, presented by Dr. Éric Bruguière, a radiologist specializing in visceral, cardiovascular and interventional imaging at the Clinique Pasteur in Toulouse, will demonstrate how AI, developed by Guerbet and integrated into Myrian®, can facilitate and secure prostate diagnosis.

"Taking part in RSNA 2024 alongside our partner Guerbet represents a strategic opportunity for Intrasense to strengthen our international network and exchange views with industry leaders on innovations in medical imaging. This congress is a key point for us to present our solutions, engage in discussions with our partners and identify new opportunities for collaboration, so that we can continue to meet the needs of healthcare professionals and patients alike."

says Alexandre Salvador, CEO of Intrasense.

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense
Salomé Sylvestre
Communications Officer
Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap
Thomas Grojean
Financial Communication
and investor relations
Phone: +331 44 71 20 40

intrasense@newcap.eu